Corey W Hunter1,2, Richard Guyer3,4, Mark Froimson5, Michael J DePalma6. 1. Ainsworth Institute of Pain Management, 115 East 57th Street, Suite 1210, New York, NY 10022, USA. 2. Department of Physical Medicine & Rehabilitation - Icahn School of Medicine; Mount Sinai Hospital, New York, NY 10029, USA. 3. Texas Back Institute Research Foundation, 6020 W. Parker Road, Suite 200, Plano, TX 75093, USA. 4. Department of Orthopedics, UT Southwestern School of Medicine, Dallas, Texas, TX 75390, USA. 5. Riverside Health Advisors, Chagrin Falls, OH 44022, USA. 6. Virginia iSpine Physicians, 9020 Stony Point Parkway, Suite 140, Richmond, VA 23235, USA.
Abstract
Aim: To explore the effects of viable allogeneic disc tissue supplementation in younger patients with discogenic chronic low back pain (CLBP). Patients & methods: VAST was a randomized placebo-controlled trial of disc allograft supplementation in 218 patients with discogenic CLBP. We conducted a post hoc analysis of change from baseline to 12 months in Oswestry Disability Index (ODI) and visual analog scale for pain intensity scores stratified by patient age. Results: Patients aged <42 years receiving allograft experienced greater improvement in ODI (p = 0.042) and a higher ODI response rate (≥10-, ≥15- and ≥20-point reductions in ODI) than those receiving saline (p = 0.001, p = 0.002 and p = 0.021, respectively). Conclusion: Young patients with discogenic CLBP may have significant functional improvement following nonsurgical disc allograft supplementation.
Aim: To explore the effects of viable allogeneic disc tissue supplementation in younger patients with discogenic chronic low back pain (CLBP). Patients & methods: VAST was a randomized placebo-controlled trial of disc allograft supplementation in 218 patients with discogenic CLBP. We conducted a post hoc analysis of change from baseline to 12 months in Oswestry Disability Index (ODI) and visual analog scale for pain intensity scores stratified by patient age. Results: Patients aged <42 years receiving allograft experienced greater improvement in ODI (p = 0.042) and a higher ODI response rate (≥10-, ≥15- and ≥20-point reductions in ODI) than those receiving saline (p = 0.001, p = 0.002 and p = 0.021, respectively). Conclusion: Young patients with discogenic CLBP may have significant functional improvement following nonsurgical disc allograft supplementation.
Entities:
Keywords:
Oswestry Disability Index; allogeneic disc tissue; allograft; degenerative disc disease; discogenic back pain; intradiscal therapy; low back pain